

Accepted Manuscript

Title: Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets

Author: Ramalingam Senthilmurugan Vidya P. Ramamurthy
Vincent C.O. Njar



PII: S0960-0760(16)30205-9
DOI: <http://dx.doi.org/doi:10.1016/j.jsbmb.2016.07.006>
Reference: SBMB 4760

To appear in: *Journal of Steroid Biochemistry & Molecular Biology*

Received date: 17-3-2016
Revised date: 8-7-2016
Accepted date: 12-7-2016

Please cite this article as: Ramalingam Senthilmurugan, Vidya P. Ramamurthy, Vincent C.O. Njar, Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets, *Journal of Steroid Biochemistry and Molecular Biology* <http://dx.doi.org/10.1016/j.jsbmb.2016.07.006>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Highlights

- Androgen deprivation therapy (ADT) is treatment of choice for recurrent PCa
- Patients eventually develop CRPC- a more advanced and resistant PCa phenotype
- Host of molecular alterations are involved in acquiring resistance to ADT and CRPC
- Array of drugs are precisely designed to target aberrant signalling pathways
- Review summarizes key aberrant pathways in PCa and therapeutics influencing them

Download English Version:

<https://daneshyari.com/en/article/5513176>

Download Persian Version:

<https://daneshyari.com/article/5513176>

[Daneshyari.com](https://daneshyari.com)